Paraldehyde

Identification

Name
Paraldehyde
Accession Number
DB09117
Description

Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 132.1577
Monoisotopic: 132.07864425
Chemical Formula
C6H12O3
Synonyms
Not Available

Pharmacology

Indication

Paraldehyde was used historically as a sedative and hypnotic 1. It has been used in the treatment of seizures as an anticonvulsant 2.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Paraldehyde blocks neuromuscular transmission 3.

Mechanism of action

Paraldehyde is believed to reduce the release of acetylcholine in response to neuronal depolarization 3. The exact mechanism of this effect is unknown.

Absorption

93% of orally administered paraldehyde is absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Paraldehyde is believed to undergo depolymerization to acetaldehyde followed by oxidation by aldehyde dehydrogenase [A19378]. It is thought to ultimately be metabolized to carbon dioxide and water.

Hover over products below to view reaction partners

Route of elimination

70-80% is metabolized to carbon dioxide and subsequently exhaled 4. 11-28% is exhaled as the parent compound. 0.1-2.5% is excreted in the urine as the parent compound.

Half-life

The mean half life is 7.5 hours in a range if 3.5-9.5 hours 4.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Paraldehyde overdosage can produce headache, nausea, drowsiness, unconsciousness, coma, severe hypotension, respiratory depression, pulmonary edema and hemorrhages, and right-side heart failure 4. Inhalation of paraldehyde can produce sore throat, headache, dizziness, nausea, drowsiness and unconsciousness but exposure via this route is rare. Chronic use is dependence forming and withdrawal proceeds similarly to ethanol withdrawal producing hallucinations and convulsions. Toxic hepatitis and nephritis have been observed during chronic use.

The acute LD50 values determined for various species are as follows 4:

Rabbit - 3.3-5 g/kg (oral) Rat - 1.5-1.65 g/kg (oral), 1.3-1.45 g/kg (i.p.) Dog - 3-4 g/kg (oral) Mouse - 2.75 (oral) Cat - 3.3 (oral)

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AclidiniumParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlosetronAlosetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
AlverineAlverine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Paraldehyde Inj Bp 100%LiquidIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1991-12-311999-08-10Canada flag
Paraldehyde Injection BPLiquidIntramuscular; IntravenousPharmascience Inc1998-09-102013-03-14Canada flag
Paraldehyde Injection BPLiquidIntramuscular; IntravenousOmega Laboratories Ltd2012-02-082015-12-11Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
N05CC05 — Paraldehyde
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as trioxanes. These are compounds containing a six-member aliphatic saturated heterocycle made up of three oxygen atoms and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Trioxanes
Sub Class
Not Available
Direct Parent
Trioxanes
Alternative Parents
Oxacyclic compounds / Acetals / Hydrocarbon derivatives
Substituents
1,3,5-trioxane / Acetal / Aliphatic heteromonocyclic compound / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Oxacycle
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
trioxane (CHEBI:27909)

Chemical Identifiers

UNII
S6M3YBG8QA
CAS number
123-63-7
InChI Key
SQYNKIJPMDEDEG-UHFFFAOYSA-N
InChI
InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3
IUPAC Name
2,4,6-trimethyl-1,3,5-trioxane
SMILES
CC1OC(C)OC(C)O1

References

General References
  1. Lopez-Munoz F, Ucha-Udabe R, Alamo C: The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005 Dec;1(4):329-43. [PubMed:18568113]
  2. Rowland AG, Gill AM, Stewart AB, Appleton RE, Al Kharusi A, Cramp C, Yeung LK: Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. Arch Dis Child. 2009 Sep;94(9):720-3. doi: 10.1136/adc.2009.157636. Epub 2009 Apr 8. [PubMed:19357123]
  3. NICHOLLS JG, QUILLIAM JP: The mechanism of action of paraldehyde and methylpentynol on neuromuscular transmission in the frog. Br J Pharmacol Chemother. 1956 Jun;11(2):151-5. [PubMed:13329331]
  4. Von Burg R, Stout T: Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81. [PubMed:1783744]
Human Metabolome Database
HMDB0032456
KEGG Compound
C07834
PubChem Compound
31264
PubChem Substance
310265034
ChemSpider
21106173
RxNav
7909
ChEBI
27909
ChEMBL
CHEMBL1410743
ZINC
ZINC000000001886
Wikipedia
Paraldehyde
MSDS
Download (89.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentConvulsions / Refractory seizure disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidIntramuscular; Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)12Von Burg R, Stout T: Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81.
boiling point (°C)124Von Burg R, Stout T: Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81.
water solubility125g/LVon Burg R, Stout T: Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81.
logP0.73MSDS
Predicted Properties
PropertyValueSource
Water Solubility177.0 mg/mLALOGPS
logP0.33ALOGPS
logP0.88ChemAxon
logS0.13ALOGPS
pKa (Strongest Basic)-4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area27.69 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity32.09 m3·mol-1ChemAxon
Polarizability14.15 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0005-9000000000-a3f03c0baa80a3369e84
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Electron carrier activity
Specific Function
Not Available
Gene Name
ALDH2
Uniprot ID
P05091
Uniprot Name
Aldehyde dehydrogenase, mitochondrial
Molecular Weight
56380.93 Da
References
  1. Von Burg R, Stout T: Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81. [PubMed:1783744]

Drug created on September 22, 2015 13:31 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates